Drug intelligence / Profile preview

TNX-701

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Small Molecules

Overview

**TNX-701** is an undisclosed small molecule developed by Tonix Pharmaceuticals as a medical countermeasure to prevent radiation effects and improve biodefense capabilities. It is in the preclinical stage with no detailed public information available on its mechanism of action, chemical structure, or specific indications beyond radiation protection. The program was advanced following Tonix's acquisition of related assets, positioning it as part of their pipeline for non-opioid pain and biodefense applications.[7][9][13]

Beyond the preview

Go deeper on TNX-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-701.

Explore the full profile